Floatz logo

Rivaroxaban

Portal Vein Thrombosis

Sherief Abd-ElsalamSmall moleculePhase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Portal Vein Thrombosis cohort.

Asset / SponsorPhaseRating
Sorafenib
First Affiliated Hospital of Zhejiang University
Phase 4BBB
LENVATINIB
First Hospital of China Medical University
Phase 4BBB
WARFARIN
Kafrelsheikh University
Phase 4BB
NADROPARIN
Shanghai Zhongshan Hospital
Phase 4BB
Enoxaparin
Institute of Liver and Biliary Sciences, India
Phase 4BB

View all 27 →

Same molecule, other indications

Rivaroxaban is also rated in:

atrial fibrillationDormant
BBB
Indicative ·
79 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
thrombotic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →